Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
26.1×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
0.67 0.58 0.44 0.84
P/FCF ratio
0.00 0.00 177.67 53.80
P/Operating CF
26.89 80.59 73.94 60.88
P/B ratio
1.06 0.91 0.70 1.33
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
1.95 1.53 1.44 1.84
EV/EBITDA
0.00 0.00 0.00 13.56
EV/Operating CF
35.82 49.74 33.23 35.52
EV/FCF
(708.68) (80.70) 581.82 117.46
Quick Ratio
1.46 1.19 1.53 1.64
Current Ratio
3.14 2.54 3.38 3.60
Net Debt/EBITDA
29.55 24.86 30.67 26.60
Debt/Assets
49.15% 50.45% 51.06% 51.32%
Debt/Equity
1.73 1.74 1.75 1.75
Asset Turnover
0.43 0.43 0.43 0.46
Operating CF/Net income
(7.57) (6.93) (2.12) 5.09
Capex/Depreciation
(0.38) (0.44) (0.38) (0.31)
Interest Coverage
0.52 0.97 0.51 0.84
Research and Development Expense of Revenue
5.59% 5.70% 6.00% 5.79%
Selling, General and Administrative Expense of Revenue
42.04% 38.92% 45.48% 41.18%
Intangible Assets out of Total Assets
0.49 0.49 0.48 0.47
Share Based Compensation of Revenue
1.39% 1.34% 1.32% 1.40%
Graham Net Nets
(1.33) (1.47) (1.88) (0.96)
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(45.08%) (54.19%) (68.58%) (0.50%)
Free Cash Flow Yield
(0.41%) (3.26%) 0.56% 1.86%
Revenue per Share
5.24 5.67 5.09 5.42
Operating CF per Share
0.53 0.15 0.13 0.30
Capex per Share
(0.20) (0.22) (0.19) (0.16)
Free Cash Flow per Share
0.34 (0.07) (0.07) 0.14
Cash per Share
3.49 3.44 3.45 3.55
Shareholders Equity per Share
13.52 13.61 13.55 13.50
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
13.52 13.61 13.55 13.50
Free Cash Flow
25.75 (5.40) (5.04) 10.50
Working Capital
779.53 703.56 825.17 860.60
Capital Expenditures
(15.16) (17.21) (14.85) (12.31)
Net Current Asset Value
(1,465.30) (1,398.99) (1,363.30) (1,328.63)
EV/EBIT
0.00 0.00 0.00 46.23
Capex to Sales
0.04 0.04 0.04 0.03
Price to Operating Income
0.00 0.00 0.00 21.18
Other line items
Average Receivables
255.23 275.61 258.43 275.85
Average Payables
84.99 89.11 89.62 87.74
Average Inventory
463.02 460.91 470.23 478.57
Average Assets
3,856.13 3,819.71 3,815.24 3,615.70
Average Common Equity
1,279.58 1,294.37 1,283.27 1,041.02

Fold the line items

Columns are period end dates